The Japanese health ministry reported its plans to add pediatric usages for three immune thrombocytopenic purpura (ITP) drugs at a key advisory panel meeting on October 31, with the products inching closer to an official seal of approval for their…
To read the full story
Related Article
- Keytruda, Arexvy, Imfinzi, Lynparza Broaden Labels in Japan
November 25, 2024
REGULATORY
- Japan Panel Seeks Easing of Rules on Radiopharma Research Samples
June 16, 2026
- LDP Team Reviews Draft Industry Cluster Plans for Radiopharma, Blood Products
June 16, 2026
- DPP Calls for End to Off-Year Drug Price Cuts, Chuikyo Reform
June 15, 2026
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





